Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
Replay the moments of Euro Convergence 2020. Recorded sessions are available to attendees until 31 January 2020.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS website recently experienced issues that we continue to monitor. Certain areas of the site including news may be limited. We apologize for any inconvenience.
Posted 08 October 2015 | By Michael Mezher
The European Medicines Agency's (EMA) mid-year report, detailing the agency's activities through 30 June 2015, reveals that the agency met or was ahead of most metrics covered, despite a decline in the number of new non-orphan drugs and a sharp rise in the number of GMP inspections conducted.
EMA uses a four-colored "traffic light" system to rate its workload and performance against its forecast goals. Depending on the result for each indicator, the agency has either maintained or revised its forecast figure to match its expectations for the remainder of the year.
In the system, a blue circle indicates a result of more than 10% above the agency's forecast, green indicates a result within 10% of the forecast, orange indicates a result was off by 10-25% and red indicates results were off by more than 25%.
While these indicators can give a general sense of the EMA's workload and performance, the agency cautions that the system does not paint the whole picture.
In the first half of 2015 EMA saw an increase in the number of requests for scientific and protocol assistance from 2014.
The agency also saw a slight decrease in the number of applications for orphan designation, 120, down from 138 for the same period in 2014.
EMA says it met most of its performance goals for its pre-authorization activities and completing 100% of its scientific procedures within their allotted timeframes. However, the agency notes it received a smaller-than-expected increase in requests for scientific advice and saw fewer applications receiving orphan designation than expected.
For initial evaluations in the first half of 2015, EMA saw an increase from the same period in 2014 in all areas except for new non-orphan medicinal products. The agency was initially expecting to receive 48 applications for new non-orphan medicinal products; however, by the end of June the agency had only received 14, prompting it to revise its forecast to 40.
The agency also met its target of evaluating all applications within their legal timeframes, and met its goal of reviewing new drugs and biosimilars in 205 on average.
For inspections and compliance, EMA beat or came within striking distance of most of its targets.
While EMA was right on target for good laboratory practice (GLP) and good clinical practice (GCP) inspections, the agency noted a 67% increase in the number of good manufacturing practice (GMP) inspections it carried out over the same period in 2014. Additionally, the agency was on target for all its performance metrics related to inspections and compliance, meeting or besting its goals in each area.
For 2015, EMA has introduced new workload indicators for its involvement with the media and press:
EMA missed its expected workload for both the number of requests for interviews and comments by media representatives and the number of press releases/news items. In both cases the agency revised its forecast down, by 33% and 25% respectively.
EMA Mid-Year Report 2015
Tags: EMA, regulatory reports, GMP inspections
Regulatory Focus newsletters
All the biggest regulatory news and happenings.